Clinical therapeutic trials are experimental studies in humans designed to compare the therapeutic benefits of two or more interventions (e.g., treatment vs placebo, treatment vs treatment).
Study quality improves when trials are:
- Randomized (subjects randomly assigned to groups)
- Controlled (comparison with placebo or standard therapy)
- Double-blinded (neither subject nor researcher knows group assignment)
- Triple-blinded (data analysts are also blinded)
Types of Clinical Trial Designs
| Design | Description | Bias Risk |
|---|---|---|
| Crossover Trial | Subjects receive ≥ 2 treatments in random order. Washout period between treatments allows subjects to serve as their own controls. | ↓ Bias |
| Intention-to-Treat Analysis | Subjects were analyzed according to their original randomized group, regardless of adherence. Minimizes bias due to attrition/crossover. | ↓ Bias, but the effect may appear diluted |
| As-Treated Analysis | Subjects were analyzed according to the treatment they actually received. | ↑ Bias |
| Per-Protocol Analysis | Only subjects who completed treatment per the original assignment are analyzed. | ↑ Bias |
Phases of Clinical Trials
| Phase | Sample | Main Goal | Key Point |
|---|---|---|---|
| Preclinical | Lab animals & in vitro | Biological activity, toxicity | Before human testing |
| Phase 0 | Very small number, microdosing | Pharmacokinetics & pharmacodynamics | Often skipped |
| Phase 1 | A small number of healthy volunteers or patients | Safety (Is it Safe?) & maximum tolerable dose | Open-label |
| Phase 2 | A moderate number of patients with the disease | Efficacy (Does it Work?) | Randomized, controlled |
| Phase 3 | A large number of patients with the disease | Effectiveness (Any Improvement vs standard care?) | Randomized, controlled |
| Phase 4 | Postmarketing surveillance | Long-term safety (Can it stay on the Market?) | Detects rare or late adverse effects |
Key Takeaways
- Crossover trials reduce variability since subjects serve as their own controls.
- Intention-to-treat is the gold standard for analysis.
- Phase 1–4 trials progress from safety → efficacy → effectiveness → surveillance.
Learning Objective:
Be able to differentiate between clinical trial designs and phases and identify which phase or analysis method is being described in a question stem, especially in the context of drug safety, efficacy, and postmarketing surveillance.
